Chemotherapy versus supportive care alone in pediatric palliative care for cancer: comparing the preferences of parents and health care professionals
D Tomlinson, U Bartels, J Gammon, PS Hinds, J Volpe… - Cmaj, 2011 - Can Med Assoc
Background: The choice between palliative chemotherapy (defined as the use of cytotoxic
medications delivered intravenously for the purpose of our study) and supportive care alone is …
medications delivered intravenously for the purpose of our study) and supportive care alone is …
A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid …
D Stempak, J Gammon, J Halton… - Journal of pediatric …, 2006 - journals.lww.com
Tumor vasculature is a reasonable target for cancer therapy and lower more frequent doses
of traditional chemotherapeutics [low-dose metronomic (LDM) chemotherapy] has been …
of traditional chemotherapeutics [low-dose metronomic (LDM) chemotherapy] has been …
Hospital and home chemotherapy for children with leukemia: A randomized cross‐over study
…, M Booth, S Daub, A Gafni, J Gammon… - Pediatric blood & …, 2006 - Wiley Online Library
Background The study objective was to compare a hospital‐based and a home‐based
chemotherapy program for children with acute lymphoblastic leukemia (ALL) in relation to Quality …
chemotherapy program for children with acute lymphoblastic leukemia (ALL) in relation to Quality …
Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma
…, J Kuttesch, D Strother, S Baruchel, J Gammon… - Neuro …, 2014 - academic.oup.com
Background The prognosis of diffuse intrinsic pontine glioma (DIPG) remains poor, with no
drug proven to be effective. Methods Patients with clinically and radiologically confirmed, …
drug proven to be effective. Methods Patients with clinically and radiologically confirmed, …
Single‐dose and steady‐state pharmacokinetics of celecoxib in children
D Stempak, J Gammon, J Klein… - Clinical …, 2002 - Wiley Online Library
Background and Objective Celecoxib is a member of a novel group of agents that selectively
inhibit cyclooxygenase 2 (COX‐2). COX‐2 inhibitors have emerged as an important class of …
inhibit cyclooxygenase 2 (COX‐2). COX‐2 inhibitors have emerged as an important class of …
Health-related quality of life and enrollment in phase 1 trials in children with incurable cancer
M Barrera, N D'AGOSTINO, J Gammon… - … & supportive care, 2005 - cambridge.org
Objectives: To investigate health-related quality of life (HRQOL) in children eligible for
Phase 1 trials and the reasons why families consider participating in these trials.Methods: …
Phase 1 trials and the reasons why families consider participating in these trials.Methods: …
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma
JR Sharp, E Bouffet, D Stempak, J Gammon… - European journal of …, 2010 - Elsevier
PURPOSE: Survival rates for paediatric diffuse intrinsic brainstem glioma (DIBSG) are dismal.
Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may …
Metronomic dosing of temozolomide (TMZ) combined with standard radiotherapy may …
Children receiving chemotherapy at home: perceptions of children and parents
…, S Daub, A Gafni, J Gammon… - Journal of pediatric …, 2006 - journals.sagepub.com
… Janet Gammon, BScN, RN, is clinical research nurse coordinator in the Hematology &
Oncology Programme, SickKids. Janet Yamada, MSc, RN, is a nursing research associate, …
Oncology Programme, SickKids. Janet Yamada, MSc, RN, is a nursing research associate, …
Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors
…, MS Irwin, GLS Sholler, J Gammon… - Pediatric blood & …, 2014 - Wiley Online Library
Background The combination of vinblastine and mammalian target of rapamycin (mTOR)
inhibitor sirolimus inhibits the growth of neuroblastoma xenografts through pro‐apoptotic and …
inhibitor sirolimus inhibits the growth of neuroblastoma xenografts through pro‐apoptotic and …
Parental decision making in pediatric cancer end-of-life care: using focus group methodology as a prephase to seek participant design input
D Tomlinson, M Capra, J Gammon, J Volpe… - European Journal of …, 2006 - Elsevier
The ultimate aim of our research program is to provide strategies that facilitate parental
decision-making for parents of children with cancer receiving end-of-life care. As a first step to …
decision-making for parents of children with cancer receiving end-of-life care. As a first step to …